ABSTRACT
INTRODUCTION
PLD plays an important role in the membrane trafficking, endocytosis, cell growth, differentiation, inflammatory response, and other cellular functions [1] . The involvement and the regulation of PLD activity in the cellular processes have been intensively studied in the past decade. Altered PLD activity causes the change of the production of phosphatidic acid (PA), which may lead to further changes in the levels of other intracellular second messengers or lipid bioactive molecules through the metabolic conversion catalyzed by different enzymes. Phosphatidylcholine (PC)-specific PLD catalyzes the hydrolysis of PC and generates choline and PA, the latter can be further hydrolyzed to DAG by the action of a PA phosphatase. PA itself is an intracellular bioactive molecule, which is involved in the cell growth, differentiation, and other cellular functions [2] , [3] . Lysophosphatidic acid (LPA), a potent signaling molecule which acts through G-protein coupled receptors, can be generated by the action of a phospholipase A 2 . It has been known that LPA is implicated in a variety of cellular functions [4] , [5] , including stimulation of cell proliferation and differentiation, Ca 2+ mobilization, tumor cell invasion in vivo, chemotaxis, and other functions. The regulation of PLD activity and subsequent generation of different lipid signaling molecules is therefore a very important signaling event, which may be implicated in the interactions among different signaling pathways and in achieving the signaling specificity. PLD activity can be regulated by various factors, including PKC, GTP-binding proteins, Ca 2+ , ADP-ribosylation factors, ceramide, PIP2. [1] , [6] [7] [8] . Many growth factors for receptor tyrosine kinases, including the epidermal growth factor (EGF), platelet-derived growth factor (PDGF), v-Src, fibroblast growth factor (FGF), and insulin-like growth factor (IGF), have been shown to activate PLD activity [9] [10] [11] [12] [13] [14] . Activation of non-receptor tyrosine kinase v-Src has also been shown to activate PLD activity [15] . The involvement of protein kinase C in the regulation of PLD activity has been intensively studied in the past decade. Both PKC-dependent and -independent activation of PLD has been demonstrated.
TGF-β, a pleiotropic growth factor, is involved in the regulation of a variety of cell functions and physiological processes. It inhibits the growth of epithelial cells, promotes cell differentiation, and stimulates the extracellular matrix formation. TGF-β-mediated signaling is implicated in cell morphogenesis, body planning, wound healing, immunosuppression, and apoptosis [16] , [17] . The receptors of TGF-b have been identified as the serine/ threonine kinases, which are comprised of three different types. The mechanism of the TGF-b-mediated signaling at the receptor level has been well characterized in the past several years. A major concern of the current studies in TGF-β signaling area is the postreceptor signaling events and the interactions between different signaling components. The progress in this respect may provide insight into the mechanism for achieving the signaling specificity and diversity in TGF-b-mediated biological processes [18] . G proteins and MAPKs have been reported to be the downstream components of signaling mediated by TGF-β family members. It is known that different type I receptor can interact with a single type II receptor [19] . Studies on the TGF-β receptor-interacting proteins and the cloning and functional characterization of a family of Smad proteins in the last few years increased our understanding of the TGF-β-mediated signaling pathway [20] [21] [22] . Activation of receptor serine-threonine kinase activity leads to the phosphorylation of specific Smad proteins and translocation of heteromeric Smad protein complexes to the nucleus. Smads can associate with various nuclear transcription factors, and themselves have DNA binding capability and transcriptional transactivation activity. Once in the nucleus, Smads function in the activation or suppression of the transcription of specific target genes. Smadsmediated signaling is implicated in cell growth, differentiation, and apoptosis. It is not clear if other signaling molecules are involved in the downstream signaling of TGF-β. The involvement and significance of the lipid signaling events in the TGF-β-mediated cell growth inhibition also remains to be identified. Here we studied the effects of TGF-β 1 on the PLD activity and the formation of DAG in several lines of epithelial cells whose growth can be inhibited by TGF-β. 
MATERIALS AND METHODS

Methods
Cell Culture and labeling
A-549 cells were cultured in F-12K medium containing 10 % new born calf serum. MDCK cells were cultured in MEM with Earle s BSS containing 5 % NCS, 5 % FCS. Mv1Lu cells were cultured in MEM with Earle s BSS and nonessential amino acid containing 5 % NCS, 5 % FCS. All cell cultures contain penicillin (100 U/ml)/streptomycin (100 g/ml). Cells were grown in 60 mm plate a t 37 o C, under 5 % CO 2 . For measuring the PLD acti vi ty or the DAG/ PA derived from phosphatidylcholine, 80-90 % confluent cell cultures were made quiescent by maintaining cells in 1.5 ml DMEM containing 0.5 % newborn calf serum for 24 h. The cells were then labeled with 3-4 βCi [
3 H]-myristic acid overnight. For measuring the DAG derived from phosphatidylinositol phosphates, cells were labeled with 2 μCi [
3 H]-arachidonic acid overnight. When necessary, the original labeling materials were concentrated through Speed-Vac concentrator to make the final ethanol concentration in the medium less than 0.1 %.
Determination of PLD activity and the production of DAG
Lipids were extracted and analyzed as previously described [15] with minor modifications. Reactions were stopped by quickly pouring off the medium and treating the cells with 600 l of ice-cold CH 3 OH/ 6 N HCl (50:2, v:v). Samples were carefully scraped and moved into Eppendorf tubes and extracted with the same volume of ice-cold CHCl 3 . Phase separation was made by adding 200 μl of NaCl solution (1M), mixed and votexed. The organic phase was transferred to another Eppendorf tube and re-extracted with ice-cold NaCl (0.35 M, 600 μl) and CH3OH/6 N HCl (50:2, v:v, 200 μl). The organic phase was dried by Speed-Vac concentrator. Extracted lipid samples were redissolved in 30-40 μl of CHCl 3 /CH 3 OH (95:5) and applied to Silica-gel 60Å TLC plate. The lipids were separated by different solvent systems: For PA and PBut, the upper phase of ethylacetateisooctane-acetic acid-water (90:50:20:100, solvent system I); for DAG and monoacylglycerol MG, hexane:diethylether:methanol:acetic acid (90:20:3:2, solvent system II). For PA, PBut, MG, and DAG, lipid samples were separated twice with solvent system I (at each time, chromatography was stopped when the solvent front reaches the middle of the TLC plate) and once with the solvent system II. The plate was lightly stained with iodine vapour and the standard lipids were marked. Plate was sprayed with EN 3 ANCE spray and exposed by autoradiography with a Kodak film at -80 o C. Specific lipids were identified with the references of the migration of lipid standards and were scrapped from TLC plates into scintillation vials. Lipids were eluted out of the silica gel by adding 0.5 ml CH 3 OH and then mixed with 2.5 ml Biodegradable Counting Scintillant (BCS, Amersham), the radioactivity was measured by liquid scintillation spectrometry.
Determination of the production of inositol phosphates 80-90 % confluent A-549 cells grown in 60 mm plates were incubated in serum-deprived F-12K medium (containing 0.5 % BSA) for two hours. Cells were then labeled with 1 μCi [
3 H]-myo-inositol in serum-deprived inositol-free F-12K medium (containing 0.5 % BSA) for 24 h. Cell were washed with PBS and incubated in the same medium without [
3 H]-myo-inositol for 50 minutes, and then treated with TGF-β 1 for the indicated times in the presence of 20 m M lithium chloride, which was added 10 min before the TGF-β 1 . The reaction was stopped and the inositol phosphates were extracted as described by Hawkins et al. [23] .
Growth inhibition assay
Cells were grown in 24-well plate to about 80 %, then incubated in 0.5 ml respective medium containing 0.5 % NCS for additional 30 h. TGF-β 1 was added at different time points during the incubation. To label the cells, [
3 H]-thymidine (0.1 ( Ci/ml) was added during the last 4 h of incubation. The incubation was terminated by pouring off the medium and washing the cells with ice-cold phosphate-buffered saline (PBS) for 3 times followed by adding 0.5 ml of 10 % trichloroacetic acid (TCA). The plates were maintained on ice for 20 minutes and washed again with ice-cold deionized water for 3 times. The acid-insoluble material was redissolved in 0.4 ml lysis buffer (1 % SDS, 0.2 N NaOH) and moved into scintillation vials, mixed with 2.5 volume of BCS. The DNA-associated [
3 H]-radioactivity was determined by liquid-scintillation spectrometry.
RESULTS AND DISCUSSION
Growth inhibitory effects of TGF-β on Mv1Lu, MDCK, and A-549 cells
Dysregulation of TGF-β signaling is linked with carcinogenesis, tumor invasion, immune diseases, and other abnormalities [16] , [17] . The downstream signaling mechanism of TGF-β -mediated inhibition of cell growth and other physiological effects has been a focus of some studies. In this study, we determined the effects of TGF-β 1 on the growth of several epithelial cell lines. Fig 1 showed that TGFβ 1 strongly inhibited the DNA synthesis of Mv1Lu, MDCK, A-549 cells in a time-dependent manner. Inhibition is maximal at the concentration of 5 ng/ml (data not shown). The inhibitory effect of TGFβ 1 on DNA synthesis of A-549 cells is not as strong as its effects found in Mv1Lu and MDCK cells.
In addition, a refractory response of A-549 cells on the prolonged TGF-β 1 treatment (usually after 2 d) was observed. These results indicate that TGF-β 1 has a different potency on the inhibition of the growth of Mv1Lu, MDCK, and A-549 cells. The results are also consistent with our observation obtained through the microscope and the crystal violet assay. Unlike the Mv1Lu and MDCK cells, A-549 is a type of cancer cells. The reduced sensitivity of A-549 cells to TGF-β treatment may account in certain extent the malignancy of these cells. Thus, investigating the signaling mechanism through which TGF-b1 differentially inhibits the growth of these cells may be helpful in the understanding of how cancer cells escape from normal growth controls. 
TGF-β 1 induces the activation of PLD activity in Mv1Lu, MDCK, and A-549 cells
It has been reported in recent years that Smads and MAP kinases play important roles in TGF-β-mediated cellular signaling and the associated biological events. Very little is known about the implications of lipid signaling pathways in TGF-β-mediated growth inhibition. It has been reported that TGF-b increases the activity of PA phosphatase-1 in rat hepatocytes [24] . To investigate whether the lipid signaling events are involved in the TGF-β 1 -mediated cell growth inhibition, we determined the PLD activity in response to the TGF-β 1 treatment. In the presence of primary alcohol, PLD also catalyzes the transphosphatidylation reaction, resulting in the formation of phosphatidylalcohol, a unique product of PLD, which has been widely used for examining the PLD activity [25] . Cells were labeled with [ 3 H]-myristate, which preferentially incorporated into the PC, and then treated with TGF-β 1 in the presence of butanol. PLD activity was determined as measured by the formation of PBut. As shown in Fig 2, treatment of MDCK, Mv1Lu , and A-549 cells with TGF-β 1 , resulted in a slow but persistent increase of PBut in these cells, which could be detected after 2 h and does not decrease within the 16 h of incubation. These results suggest that increased PLD activity may be involved in the TGF β 1 -induced inhibition of cell growth. In other experiments, we also found that TGF-β 1 stimulates PLD activity in A-431 cells (data not shown). Since TGF β 1 -induced growth inhibition and apoptosis of cells require the synthesis of new proteins and TGF-β 1 -induced gene expression (manuscript submitted), PLD activation may likely to be regulated by an intermediary component in TGF-β induced signaling events. However, the specific function of PLD in TGF-β 1 -mediated biological events has to be characterized. Effect of TGF-β 1 on PLD activity. [
3 H]-myristic acid-labeled cells grown in 60 mm plates were stimulated with TGF-b1 (5 ng/ml) for the indicated time in the presence of 0.4 % of butanol. The lipids were extracted and analyzed as described in Materials and Methods section. PLD activity was determined as measured by the formation of PBut. The data are the means SD of 3 independent done in duplicates. All values were normalized to respective nontreated controls which were designed as 1 fold.
In Fig 3, a corresponding increase in the PA level in MDCK cells treated with TGF-TGF-β 1 induced growth inhibition and PLD activation 1 was shown. The increase of PA level in A-549 cells is not as obvious as that of the PBut, and no increase of PA was detected in Mv1Lu cells. The discrepancy between the increase of PBut and the PA is probably due to the fact that the metabolic conversion of PA in the cells is rapid, and the rates of metabolic conversion of PA are likely to be different in different cells. The changes in the PA production are thus more difficult to be accurately detected as compared with that of the PBut. It is believed that TGF-does not interfere with the early signaling events induced by growth factors. In our studies, no effect of TGF-on the fetal calf serum-, EGF-, and PMA-induced activation of PLD was observed. Effects of TGF-1 on the PC-and PIPs-derived DAG formation Altered PLD activity could influence the level of intracellular second messenger DAG, which is formed through PA phosphatase-catalyzed hydrolysis of PA. DAG plays an important role in cellular growth and other functions, which acts as a physiological activator for some PKC isoforms [26] and has been shown to be a direct Ca 2+ ion channel regulator [27] . Though it has been reported that PC-PLC are involved in the TGF-1 -mediated signaling or growth inhibition [28] , [29] , the effects of TGF-on the phospholipase activity and the DAG production has not been determined. To investigate whether the TGF--mediated increase of PLD activity leads to concomitant increase in the level of DAG, we determined the formation of PC-derived DAG labeled by [ 3 H]-myristate. As shown in Fig 4 , a gradual increase in the production of DAG induced by TGF-β 1 was observed in MDCK cells. TGF-β 1 only slightly increases the DAG production in A-549 cells. Whereas, no increase of DAG production was detected in Mv1Lu cells. DAGs generated from PIPs and PC have different biological properties, which suggests a different biological significance [12] . In this study, we also determined the effect of TGF-β on the production of DAG derived from PIPs. As shown in Fig 5, TGF-β does not stimulate the formation of PIPs-derived DAG in the cells examined. Only a very weak increase in TGF-β 1 -treated A-549 cells was observed. Consistent with these results, similar results were obtained on the TGF-b1-stimulated production of inositol phosphates in A-549 cells labeled with [ 3 H]-inositol (data not shown). The results indicate that phosphatidylinositol specific phospholipase C is not involved in the TGF-β -mediated growth inhibition in these cells. It is not clear whether the different effects of TGF-β 1 on the PA and DAG levels of these cells result from the cell-specificity or the differential metabolic conversion of PA. Though all of the three cell lines used in this study are epithelial cells, they were from different species and different tissues. Mv1Lu is a mink lung epithelial cell line, whose growth can be most easily inhibited by TGF-β. As a canine kidney cell line, MDCK has a distinct polarized cellular structure, whereas, A-549 cells are derived from human lung carcinomatous tissure. The observation that human TGF-b1 increases the PLD activity in these three different cells suggests that PLD is one of the components of TGF-β-induced signaling pathway. The precise relationships between the TGF-β-induced activation and its anti-proliferate effect also remain unidentified. In summary, the present study demonstrates that TGF-β increases the PLD activity in MDCK, A-549, and Mv1Lu cells. Corresponding increases of PA and PC-derived DAG levels were also observed in MDCK and A-549 cells. The data indicate that PLD activation is involved in TGF-β 1 -induced growth inhibition in these cells. Since PA itself is an intracellular second messenger and the metabolic conversion of PA can generate different lipid signaling molecules, further characterization of the roles of PLD activity is therefore important in a better understanding of the mechanisms through which TGF-β regulates cell growth, differentiation, and apoptosis. 3 H]-AA for 16 h. DAG was extracted and measured as described in Fig 4. The data are the means SD of 2 independent experiments (one experiment was performed in duplicates, another one was performed in triplicates). All values were normalized to respective nontreated controls. AA, arachidonic acid.
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